Global Ingredient Risk Index Metabolic

L-Valine

L-Valine (2-amino-3-methylbutanoic acid)

Also known as: valine, L-valine BCAA, branched chain amino acid valine

25 მარ 2026

LOW RISK 2.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.0/10).

Known Safety Concerns

Maple syrup urine disease (MSUD) -- absolute contraindication
High doses may affect tryptophan/serotonin metabolism
High protein intake caution in renal disease

Contraindications

Maple syrup urine disease (MSUD) -- absolute contraindication
High doses may affect tryptophan/serotonin metabolism

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

L-valine is a branched-chain essential amino acid important for protein synthesis and energy metabolism in muscle. Well-tolerated at supplemental doses. Maple syrup urine disease (MSUD) is a contraindication.

Scientific Name: L-Valine (2-amino-3-methylbutanoic acid)

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Metabolic

Key Safety Concern Maple syrup urine disease (MSUD) -- absolute contraindication

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Metabolic

Main Safety Concern Maple syrup urine disease (MSUD) -- absolute contraindication

Ingredient L-Valine

Scientific name L-Valine (2-amino-3-methylbutanoic acid)

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Metabolic
Evidence consistency: High consistency across studies (100%)

Safety Signals

Maple syrup urine disease (MSUD) -- absolute contraindication
High doses may affect tryptophan/serotonin metabolism
High protein intake caution in renal disease

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for L-Valine indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient L-Valine

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name L-Valine (2-amino-3-methylbutanoic acid)

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 25 მარ 2026, 22:50

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Integrating metabolomics and metagenomics reveals potential mechanism of rice root exudates in inhibiting nitrification in coastal saline soils. ↗

PMID 41819201 ↗

Journal Environ Res

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41819201/

Jiang J et al.. Integrating metabolomics and metagenomics reveals potential mechanism of rice root exudates in inhibiting nitrification in coastal saline soils.. Environ Res. 2026. PMID:41819201.
Observational / other LOW evidence YELLOW
[UHPLC-Orbitrap-MS and targeted metabolomics reveal chemical distribution characteristics and main chemical content of Tibetan medicine Liuwei Muxiang Pills]. ↗

PMID 41814839 ↗

Journal Zhongguo Zhong Yao Za Zhi

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41814839/

Duo JJ et al.. [UHPLC-Orbitrap-MS and targeted metabolomics reveal chemical distribution characteristics and main chemical content of Tibetan medicine Liuwei Muxiang Pills].. Zhongguo Zhong Yao Za Zhi. 2026. PMID:41814839.
Observational / other LOW evidence YELLOW
Effect of solid-state fermentation on protein content, amino acid digestibility and anti-nutritional components of common beans, lentils and chickpeas. ↗

PMID 41794452 ↗

Journal Food Res Int

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41794452/

Lux A et al.. Effect of solid-state fermentation on protein content, amino acid digestibility and anti-nutritional components of common beans, lentils and chickpeas.. Food Res Int. 2026. PMID:41794452.
Observational / other LOW evidence YELLOW
Precursor balancing by reprogramming pyruvate synthesis for high-yield l-isoleucine production in engineered Escherichia coli. ↗

PMID 41740936 ↗

Journal Bioresour Technol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41740936/

Huo X et al.. Precursor balancing by reprogramming pyruvate synthesis for high-yield l-isoleucine production in engineered Escherichia coli.. Bioresour Technol. 2026. PMID:41740936.
Observational / other LOW evidence YELLOW
Multistep metabolic engineered Klebsiella oxytoca for efficient l-leucine production. ↗

PMID 41704463 ↗

Journal Synth Syst Biotechnol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41704463/

Sun W et al.. Multistep metabolic engineered Klebsiella oxytoca for efficient l-leucine production.. Synth Syst Biotechnol. 2026. PMID:41704463.
Observational / other LOW evidence YELLOW
Lactobacillus plantarum (LPsca12) enhances growth phenotype and muscle nutrition in abalone (Haliotis discus hannai) by modulating microbial function and metabolism through the… ↗

PMID 41634812 ↗

Journal Anim Microbiome

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41634812/

He Y et al.. Lactobacillus plantarum (LPsca12) enhances growth phenotype and muscle nutrition in abalone (Haliotis discus hannai) by modulating microbial function and metabolism through the Amino Acid-Driven Gut-Muscle Axis.. Anim Microbiome. 2026. PMID:41634812.
Observational / other LOW evidence YELLOW
Enhancing Spore Inactivation: Low-Intensity Pulsed Electric Field Combined with Ohmic Heating and Germinant Pretreatment. ↗

PMID 41596829 ↗

Journal Foods

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41596829/

Xu FY et al.. Enhancing Spore Inactivation: Low-Intensity Pulsed Electric Field Combined with Ohmic Heating and Germinant Pretreatment.. Foods. 2026. PMID:41596829.
Observational / other LOW evidence YELLOW
Chloracidobacterium validum sp. nov., a thermophilic chlorophotoheterotrophic bacterium of the phylum Acidobacteriota from an alkaline hot spring microbial mat, represents Chloracidobacterium gen.… ↗

PMID 41553838 ↗

Journal Int J Syst Evol Microbiol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41553838/

Saini MK et al.. Chloracidobacterium validum sp. nov., a thermophilic chlorophotoheterotrophic bacterium of the phylum Acidobacteriota from an alkaline hot spring microbial mat, represents Chloracidobacterium gen. nov., Chloracidobacteriaceae fam. nov. and Chloracidobacteriales ord. nov.. Int J Syst Evol Microbiol. 2026. PMID:41553838.
Observational / other LOW evidence YELLOW
Enhanced Longevity and Immunity in Caenorhabditis elegans through Ingestion of Lactiplantibacillus plantarum SKO-001: A Multi-Omics Study. ↗

PMID 41821702 ↗

Journal Food Sci Anim Resour

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41821702/

Lee DJ et al.. Enhanced Longevity and Immunity in Caenorhabditis elegans through Ingestion of Lactiplantibacillus plantarum SKO-001: A Multi-Omics Study.. Food Sci Anim Resour. 2025. PMID:41821702.
Observational / other LOW evidence YELLOW
l-Valine ethyl ester hydro-chloride. ↗

PMID 41551121 ↗

Journal IUCrdata

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41551121/

Van Rooyen E et al.. l-Valine ethyl ester hydro-chloride.. IUCrdata. 2025. PMID:41551121.

Q × L × D × S × 10 = 2.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.0 / 10

Final GIRI Score for L-Valine. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

LOW RISK 2.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

2.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for L-Valine

A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

L-Valine

Safety Profile

Known Safety Concerns

Contraindications

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Low classification for L-Valine

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში